A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Eculizumab-Aeeb (BKEMV)

Eculizumab-Aeeb blocks complement system activation to treat rare blood and immune disorders.

First FDA approval2025-03-01
Generic availableNo (brand-only)
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one
Lowest NADAC
/unit
0 NDCs benchmarked, lowest of all strengths.
Average NADAC
Across all dosage forms in distribution.
Highest NADAC
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema9 entries indexed · 4 visible
What is Eculizumab-Aeeb used for?

Eculizumab-Aeeb blocks complement system activation to treat rare blood and immune disorders.

Is there a generic for Eculizumab-Aeeb?

No. Eculizumab-Aeeb is brand-only with no generic equivalents currently in market.

How much does my plan pay for Eculizumab-Aeeb?

NADAC pricing data not currently available for this drug.

Is Eculizumab-Aeeb on the FDA shortage list?

No. Eculizumab-Aeeb is not currently on the FDA Drug Shortage Database.

5 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Complement Inhibitor6 alternatives in D1
01
Eculizumab
Brand: SOLIRIS
Lowest NADAC
0Generic mfrs
$273.2MCY24 Part D spend
Compare →
02
Eculizumab-Aagh
Brand: EPYSQLI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
03
Pegcetacoplan
Brand: Empaveli
Lowest NADAC
0Generic mfrs
$41.1MCY24 Part D spend
Compare →
04
Pozelimab
Brand: VEOPOZ
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Ravulizumab
Brand: Ultomiris
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
06
Zilucoplan
Brand: ZILBRYSQ
Lowest NADAC
0Generic mfrs
$90.6MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book · NADAC unit costs: CMS NADAC weekly file · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.